Elite Pharmaceuticals Files 8-K
Ticker: ELTP · Form: 8-K · Filed: Apr 2, 2026 · CIK: 0001053369
| Field | Detail |
|---|---|
| Company | Elite Pharmaceuticals INC /NV/ (ELTP) |
| Form Type | 8-K |
| Filed Date | Apr 2, 2026 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, filing
TL;DR
Elite Pharma filed an 8-K, likely routine disclosures. No major news yet.
AI Summary
Elite Pharmaceuticals Inc. filed an 8-K on April 2, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). The filing includes an 8-K form, an exhibit (EX-99.1), and associated XBRL data files. No specific financial figures or material events were detailed in the provided text.
Why It Matters
This filing indicates Elite Pharmaceuticals is providing updates or disclosures required by the SEC, though the specific content is not detailed here.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report with no immediate indication of significant financial changes or negative events.
Key Players & Entities
- ELITE PHARMACEUTICALS INC /NV/ (company) — Filer
- 0001053369 (company) — CIK number for Elite Pharmaceuticals Inc.
- 2026-04-02 (date) — Filing Date
- 165 LUDLOW AVENUE NORTHVALE NJ 07647 (location) — Mailing and Business Address
FAQ
What specific information is disclosed under Regulation FD?
The provided text does not specify the content of the Regulation FD disclosure under Item 7.01.
Are there any new financial statements or exhibits filed with this 8-K?
Yes, the filing lists an 8-K form, EX-99.1, and associated XBRL data files under Item 9.01, but their content is not detailed.
What is the CIK number for Elite Pharmaceuticals Inc.?
The CIK number for Elite Pharmaceuticals Inc. is 0001053369.
When was this 8-K filing accepted by the SEC?
The filing was accepted on April 2, 2026.
What is the business address of Elite Pharmaceuticals Inc.?
The business address is 165 Ludlow Avenue, Northvale, NJ 07647.
Filing Stats: 524 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2026-04-02 08:05:23
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ELTP OTCQB Item 7.01 Re
Filing Documents
- form8-k.htm (8-K) — 36KB
- ex99-1.htm (EX-99.1) — 8KB
- ex99-1_001.jpg (GRAPHIC) — 7KB
- 0001493152-26-014813.txt ( ) — 214KB
- eltp-20260402.xsd (EX-101.SCH) — 3KB
- eltp-20260402_lab.xml (EX-101.LAB) — 33KB
- eltp-20260402_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 April 2, 2026 Date of Report (Date of earliest event reported) ELITE PHARMACEUTICALS, INC . ELITE PHARMACEUTICALS, INC /NV/ (Exact name of registrant as specified in its charter) Nevada 001-15697 22-3542636 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 165 Ludlow Avenue , Northvale , New Jersey 07647 (Address of principal executive offices) (201) 750-2646 (Registrant's telephone number, including area code) (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share ELTP OTCQB Item 7.01 Regulation FD Disclosure. On April 2, 2026, Elite Pharmaceuticals, Inc. ("Elite" or the "Company") issued a press release to announce the launch of Elite's generic version of methadone hydrochloride 5 mg and 10 mg tablets. This product is marketed and sold under the Elite Laboratories, Inc. label. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information set forth in this Item 7.01 and contained in the press release furnished as Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and is not incorporated by reference into any of Elite's filings under the Securities Act of 1933, as amended, or the Securities Act, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated April 2, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: April 2, 2026 ELITE PHARMACEUTICALS, INC. By: /s/ Nasrat Hakim Nasrat Hakim, President and CEO